Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences Inc (NASDAQ: CSTL) develops molecular diagnostic tests that guide cancer treatment decisions through gene expression profiling. The company's news flow centers on clinical validation studies, regulatory milestones, and commercial adoption of its diagnostic products.
Key news categories for Castle Biosciences include FDA regulatory developments such as breakthrough device designations, new test launches expanding the company's diagnostic portfolio, and peer-reviewed clinical study publications demonstrating test performance. The company regularly reports ordering volume milestones that indicate market adoption, as well as payer coverage decisions that affect reimbursement.
Quarterly earnings announcements provide insight into test volume growth across the DecisionDx-Melanoma, DecisionDx-UM, and TissueCypher product lines. Partnership and licensing agreements signal strategic expansion into new diagnostic areas. Scientific conference presentations at dermatology, oncology, and gastroenterology meetings often precede published research findings.
Follow Castle Biosciences news to track developments in precision oncology diagnostics, including clinical evidence supporting gene expression testing in melanoma and Barrett's esophagus, regulatory pathways for diagnostic devices, and the commercial trajectory of molecular testing adoption in cancer care.
Castle Biosciences (Nasdaq: CSTL) has successfully closed its underwritten public offering, issuing 4,600,000 shares of common stock at a price of $58.00 per share. This includes the full exercise of the underwriters' option for an additional 600,000 shares, totaling gross proceeds of $266.8 million before expenses. The offering was managed by SVB Leerink and Baird, among others. The securities were offered under a shelf registration effective since December 14, 2020, with final prospectus details available through the SEC.
Castle Biosciences (CSTL) has priced its public offering of 4,000,000 shares at $58.00 each, expected to yield gross proceeds of $232 million. Additionally, underwriters have a 30-day option for 600,000 more shares. Closing is anticipated around December 18, 2020, subject to conditions. The offering is made under a previously effective registration statement with the SEC. SVB Leerink and Baird are leading the offering, with other firms assisting.
Castle Biosciences (Nasdaq: CSTL) has initiated a proposed underwritten public offering to sell $125 million of its common stock. The company plans to allow underwriters a 30-day option to purchase an additional $18.75 million in shares. All shares will be offered by Castle. The offering is subject to market conditions and completion timing is uncertain. SVB Leerink and Baird are leading the offering, with joint bookrunning management. This offering is part of a shelf registration statement filed with the SEC, aiming to enhance financial resources for growth.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced a clinical study showing that its DecisionDx-Melanoma test alters treatment decisions for melanoma patients (AJCC stages I-III). Published in Future Oncology, the study's findings suggest that the test improves management by indicating metastatic risk, allowing tailored follow-up care. Conducted on 112 patients, the study highlights significant changes in patient surveillance based on DecisionDx-Melanoma risk classifications. This test, validated in numerous studies, has been ordered over 64,560 times, reinforcing its impact on melanoma management.
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company, has announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. CEO Derek Maetzold and CFO Frank Stokes will present a pre-recorded investor presentation and hold virtual one-on-one meetings. The company presentation will be available on the Piper Sandler conference site from November 23 to December 3 and on Castle Biosciences' investor page. Castle specializes in personalized genomic information for dermatologic cancers.
Castle Biosciences (Nasdaq: CSTL) has announced the publication of two studies in SKIN: The Journal of Cutaneous Medicine demonstrating the clinical utility of its DecisionDx® DiffDx™-Melanoma test. The studies confirm that the test provides significant diagnostic clarity for difficult-to-diagnose melanocytic lesions, leading to improved patient management. Key results of the studies show a technical success rate of 97%, with sensitivity at 99.1% and specificity at 94.3%. The test aims to reduce unnecessary procedures while effectively identifying at-risk patients.
Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its skin cancer gene expression profile tests during the 57th Meeting of The American Society of Dermatopathology. The DecisionDx®-Melanoma test was highlighted for its ability to predict sentinel lymph node (SLN) metastasis using tumor biology, demonstrating significant predictive power (p<0.001). Additionally, the new DecisionDx® DiffDx™-Melanoma test could aid in diagnosing unclear melanocytic lesions, boasting a 99.1% sensitivity and 94.3% specificity. These advancements may enhance treatment decisions and patient management in skin cancer.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced the commercial availability of DecisionDx® DiffDx™-Melanoma, a diagnostic test designed to assist dermatopathologists in evaluating suspicious pigmented lesions. This gene expression profile test can classify lesions as benign, intermediate-risk, or malignant, with a reported accuracy of 96.6%. The test aims to enhance diagnostic clarity, potentially impacting patient treatment decisions significantly. With approximately 300,000 challenging cases yearly in the U.S., this innovation could improve patient outcomes and reduce melanoma-specific mortality risks.
Castle Biosciences (Nasdaq: CSTL) announced its participation in the ASDP 57th Virtual Annual Meeting, showcasing two significant poster presentations. The presentations include DecisionDx®-Melanoma, focusing on predictors of sentinel lymph node metastasis, and DecisionDx® DiffDx™-Melanoma, which discusses a diagnostic gene expression profile for challenging pigmented lesions. Both presentations are set for November 9 and 10, 2020, highlighting the company's commitment to advancing skin cancer diagnostics through genomic testing.
Castle Biosciences (Nasdaq: CSTL) is set to release its third-quarter financial results on November 9, 2020. The results will be available after market close, followed by a conference call and webcast at 4:30 PM ET. The company specializes in skin cancer diagnostics, providing genomic information to enhance treatment decisions. Additionally, Castle offers tests for various melanomas and is developing solutions for other cancers.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
